GlassScriptPhysician profile
J Reimherr
NPI 1437178993
$77,626.10
in general payments reported to CMS, 2019-2025
29 companies · $3,911 in 2025
The $3,911 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $13K · 2021: $17K · 2022: $9,301 · 2023: $7,519 · 2024: $3,045 · 2025: $3,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,825 · Education: $90.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,559.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,825.00 |
| Education | $90.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $18,606.54 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $13,518.89 | 2021-2025 | |
| Allergan, INC. | $9,104.62 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $8,515.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $5,801.84 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $3,490.77 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $3,037.39 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $2,881.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $2,325.66 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $2,048.56 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,947.32 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,808.33 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,115.70 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $834.39 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $757.98 | 2023-2025 | Auvelity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $390.12 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $345.00 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $223.68 | 2020-2022 | |
| Shire North American Group INC | $205.79 | 2019 | |
| Indivior INC. | $181.27 | 2022-2025 | Sublocade, Perseris |
| Idorsia Pharmaceuticals US INC | $104.58 | 2023-2025 | Quviviq, Quviviq |
| Vertical Pharmaceuticals, LLC | $96.17 | 2019-2025 | Relexxii |
| Eisai INC. | $70.27 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $66.31 | 2019 | |
| Orexo US, INC. | $63.28 | 2019-2023 | Zubsolv |
| Acadia Pharmaceuticals INC | $38.60 | 2022-2023 | Nuplazid |
| Noven Therapeutics, LLC | $17.24 | 2021 | |
| Pear Therapeutics (US), INC. | $14.53 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.42 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Reimherr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.